Cargando…

A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients

The aim of this study was to evaluate the cost-effectiveness of Anbainuo (ABN) plus methotrexate (MTX) (ABN + MTX) versus conventional disease-modifying anti-rheumatic drugs (cDMARDs) in rheumatoid arthritis (RA) patients. Forty-eight moderate to severe RA patients underwent ABN + MTX or cDMARDs tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Feng, Li, Jing-Yang, Wen, Zhen-Hua, Luo, Xiao-Wen, Deng, Li, Zhang, Liang, He, Jing-Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890288/
https://www.ncbi.nlm.nih.gov/pubmed/31770193
http://dx.doi.org/10.1097/MD.0000000000017750

Ejemplares similares